Antitumor immunity and advances in cancer immunotherapy Tomoharu SugieMasakazu Toi Special Feature 23 November 2016 Pages: 1 - 2
Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication Samantha BuruguKarama Asleh-AburayaTorsten O. Nielsen Special Feature 02 May 2016 Pages: 3 - 15
Advances in personalized cancer immunotherapy Kazuhiro KakimiTakahiro KarasakiTomoharu Sugie Special Feature 21 March 2016 Pages: 16 - 24
Possible supplemental breast cancer screening modalities Takayoshi Uematsu Special Feature 07 September 2016 Pages: 25 - 25
The need for supplemental breast cancer screening modalities: a perspective of population-based breast cancer screening programs in Japan Takayoshi Uematsu Special Feature 03 June 2016 Pages: 26 - 31
Breast cancer screening with digital breast tomosynthesis Per Skaane Special Feature 30 April 2016 Pages: 32 - 41
Melatonin, an inhibitory agent in breast cancer Elaheh NooshinfarAva Safaroghli-AzarMohammad Esmaeil Akbari Review Article 26 March 2016 Pages: 42 - 51
Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer Icro MeattiniMarina GuenziLorenzo Livi Review Article 30 March 2016 Pages: 52 - 62
Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer Katsuhiko NakatsukasaHiroshi KoyamaTetsuya Taguchi Original Article 11 January 2016 Pages: 63 - 68
A pilot study to determine the diagnostic criteria of spiculated masses for BI-RADS MRI category 5: when to perform re-biopsy after discordant pathologic result? Natsuko OnishiMasako KataokaKaori Togashi Original Article 01 February 2016 Pages: 69 - 78
Impact of young age on local control after partial breast irradiation in Japanese patients with early stage breast cancer Kazuhiko SatoYoshio MizunoTomohiko Okawa Original Article 01 February 2016 Pages: 79 - 85
The benefit of deep inspiration breath hold: evaluating cardiac radiation exposure in patients after mastectomy and after breast-conserving surgery Angela LinWaseem SharieffDo-Hoon Kim Original Article 17 February 2016 Pages: 86 - 91
Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer Katsuhiko NakatsukasaHiroshi KoyamaTetsuya Taguchi Original Article 13 February 2016 Pages: 92 - 97
A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women Hitoshi InariSatoru ShimizuMunetaka Masuda Original Article 11 February 2016 Pages: 98 - 103
Diagnostic accuracy of contrast-enhanced spectral mammography in comparison to conventional full-field digital mammography in a population of women with dense breasts Miki MoriSadako Akashi-TanakaSeigo Nakamura Original Article 04 March 2016 Pages: 104 - 110
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer Kosuke KawaguchiEiji SuzukiMasakazu Toi Original Article Open access 04 March 2016 Pages: 111 - 120
The roles of 18F-FDG-PET/CT and US-guided FNAC in assessment of axillary nodal metastases in breast cancer patients Yasuharu NakanoMasakuni NoguchiHiroshi Minato Original Article 25 March 2016 Pages: 121 - 127
The functional capacity and quality of life of women with advanced breast cancer K. KokkonenT. SaartoK. Puustjärvi-Sunabacka Original Article 22 March 2016 Pages: 128 - 136
Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer Tímea TőkésKornélia KajáryMagdolna Dank Original Article 15 March 2016 Pages: 137 - 146
Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer Tetsuhiro YoshinamiToshinari YagiFumio Imamura Original Article 24 March 2016 Pages: 147 - 151
Dietary patterns and breast cancer risk in a prospective Japanese study Reiji KojimaEmiko OkadaAkiko Tamakoshi Original Article 18 March 2016 Pages: 152 - 160
Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study Junichi KurebayashiTatsuya ToyamaTsukasa Fujimoto Original Article Open access 26 March 2016 Pages: 161 - 170